- Home
- SVRE vs TNFA Comparison
SVRE vs TNFA Comparison
Compare SVRE & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- TNFA
- Stock Information
- Founded
- SVRE 2014
- TNFA 2014
- Country
- SVRE Israel
- TNFA United States
- Employees
- SVRE N/A
- TNFA N/A
- Industry
- SVRE
- TNFA
- Sector
- SVRE
- TNFA
- Exchange
- SVRE Nasdaq
- TNFA NYSE
- Market Cap
- SVRE 883.2K
- TNFA 760.1K
- IPO Year
- SVRE 2022
- TNFA N/A
- Fundamental
- Price
- SVRE $1.25
- TNFA $0.16
- Analyst Decision
- SVRE
- TNFA
- Analyst Count
- SVRE 0
- TNFA 0
- Target Price
- SVRE N/A
- TNFA N/A
- AVG Volume (30 Days)
- SVRE 139.6K
- TNFA 3.0M
- Earning Date
- SVRE 03-21-2025
- TNFA 05-15-2025
- Dividend Yield
- SVRE N/A
- TNFA N/A
- EPS Growth
- SVRE N/A
- TNFA N/A
- EPS
- SVRE N/A
- TNFA N/A
- Revenue
- SVRE $462,071.00
- TNFA N/A
- Revenue This Year
- SVRE $458.76
- TNFA N/A
- Revenue Next Year
- SVRE $106.57
- TNFA N/A
- P/E Ratio
- SVRE N/A
- TNFA N/A
- Revenue Growth
- SVRE N/A
- TNFA N/A
- 52 Week Low
- SVRE $1.17
- TNFA $0.15
- 52 Week High
- SVRE $170.36
- TNFA $2.24
- Technical
- Relative Strength Index (RSI)
- SVRE 31.70
- TNFA 37.30
- Support Level
- SVRE $1.20
- TNFA $0.16
- Resistance Level
- SVRE $1.42
- TNFA $0.18
- Average True Range (ATR)
- SVRE 0.15
- TNFA 0.02
- MACD
- SVRE 0.02
- TNFA 0.00
- Stochastic Oscillator
- SVRE 9.88
- TNFA 13.43
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.